Related News

Home » World

Hormone therapy raises breast cancer deaths

WOMEN who took hormone replacement pills had more advanced breast cancers and were more likely to die from them than women who took a dummy pill, raising new concerns about the commonly prescribed drugs, US researchers said yesterday.

The study, published in the Journal of the American Medical Association, is the first to report more breast cancer deaths among women taking hormone replacement therapy.

And it contradicts prior studies that suggest women taking the drugs had less aggressive, easier-to-treat breast cancers.

"As opposed to the prevailing thought of two years ago, that cancers associated with estrogen plus progesterone would be favorable and not much of a problem, we are actually showing they are associated with an increased risk of death from breast cancer," Dr. Rowan Chlebowski of the Los Angeles Biomedical Research Institute, who led the study, said in a telephone interview.

The findings include 11 years of follow-up from the Women's Health Initiative study, which in 2002 found women who took estrogen plus progesterone for five years had higher rates of ovarian cancer, breast cancer, strokes and other health problems.

Sales of US market leader Wyeth's combined estrogen plus progesterone pill Prempro have fallen by about 50 percent since 2001 to around US$1 billion a year. Wyeth is now owned by Pfizer.

Chlebowski's team analyzed data on the more than 12,000 women in the study. They found twice as many taking HRT died from breast cancer -- 2.6 per 10,000 per year versus 1.3 per 10,000 women per year -- compared to women who took a placebo.

Nearly 24 percent of the breast cancer patients who took HRT had tumors that had spread to the lymph notes, compared with 16 percent of women taking placebos.

"All the scary cancers with unfavorable prognoses were also increased," Chlebowski said, citing increases in aggressive forms of breast cancer, and not just estrogen-fed cancers that are easier to treat.

"And then for the first time we show deaths from breast cancer are significantly increased as well," he said.

Pfizer said in a statement the company stands behind Prempro's current labeling, which advises doctors to prescribe the drug at the lowest effective dose for the shortest possible period of time.

But even that may be risky, suggests Dr. Peter Bach of Memorial Sloan-Kettering Cancer Center in New York, who wrote a commentary in the same journal.

Doctors can only be guessing that taking the pills at a lower dose and for a shorter time would be less harmful, Bach said in a telephone interview.




 

Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend